PMID- 28837832
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20181126
IS  - 1872-7603 (Electronic)
IS  - 0165-0378 (Linking)
VI  - 122
DP  - 2017 Aug
TI  - Factors associated with adverse pregnancy outcomes in women with antiphospholipid 
      syndrome: A multicenter study.
PG  - 21-27
LID - S0165-0378(17)30093-1 [pii]
LID - 10.1016/j.jri.2017.08.001 [doi]
AB  - The aim of this study was to understand the clinical features of antiphospholipid 
      syndrome (APS)-complicated pregnancies and evaluate risk factors for the adverse 
      pregnancy outcomes. This multicenter study evaluated live-birth rates according 
      to therapy modality for APS and risk factors of pregnancy loss in 81 pregnancies. 
      Risk factors for pregnancy complications, including premature delivery before 34 
      gestational weeks, hypertensive disorders of pregnancy, thrombocytopenia, and 
      light-for-date neonate, were evaluated in 51 women who received low dose aspirin 
      (LDA) plus unfractionated heparin (UFH) and delivered after 24 GW. The live-birth 
      rate in APS pregnancies with LDA+UFH therapy was 92.6%. A multiple logistic 
      regression analysis demonstrated that LDA+UFH therapy decreased the risk of 
      pregnancy loss (OR 0.13, 95%CI 0.03-0.62), and that a history of pregnancy loss 
      despite LDA+UFH therapy increased the risk of pregnancy loss (OR 8.74, 95%CI 
      1.69-45.2). LDA therapy prior to pregnancy decreased the risk of premature 
      delivery (OR 0.14, 95%CI 0.03-0.69). Positive tests for two or more 
      anti-phospholipid antibodies increased the risks of premature delivery (OR 9.61, 
      95%CI 1.78-51.8) and thrombocytopenia (OR 4.90, 95%CI 1.11-21.7). Laboratory 
      findings of low complements increased the risk of hypertensive disorders of 
      pregnancy (OR 12.1, 95%CI 1.61-91.0). Standard therapy yielded high live-birth 
      rates. Positive tests for two or more anti-phospholipid antibodies and low 
      complements were associated with adverse pregnancy outcomes. These results have 
      important implications for clinicians.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Deguchi, Masashi
AU  - Deguchi M
AD  - Department of Obstetrics and Gynecology, Kobe University Graduate School of 
      Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
FAU - Yamada, Hideto
AU  - Yamada H
AD  - Department of Obstetrics and Gynecology, Kobe University Graduate School of 
      Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Electronic address: 
      yhideto@med.kobe-u.ac.jp.
FAU - Sugiura-Ogasawara, Mayumi
AU  - Sugiura-Ogasawara M
AD  - Department of Obstetrics and Gynecology, Nagoya City University, Graduate School 
      of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
FAU - Morikawa, Mamoru
AU  - Morikawa M
AD  - Department of Obstetrics and Gynecology, Hokkaido University Graduate School of 
      Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-0818, Japan.
FAU - Fujita, Daisuke
AU  - Fujita D
AD  - Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigakumachi, 
      Takatsuki, Osaka 569- 8686, Japan.
FAU - Miki, Akinori
AU  - Miki A
AD  - Department of Obstetrics and Gynecology, Kitasato University Medical Center, 
      6-100 Arai, Kitamoto City, Saitama 364-8501, Japan.
FAU - Makino, Shintaro
AU  - Makino S
AD  - Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, 
      3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan.
FAU - Murashima, Atsuko
AU  - Murashima A
AD  - Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center 
      for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170804
PL  - Ireland
TA  - J Reprod Immunol
JT  - Journal of reproductive immunology
JID - 8001906
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antibodies, Antiphospholipid/metabolism
MH  - Antiphospholipid Syndrome/drug therapy/*epidemiology
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Hypertension/drug therapy/*epidemiology
MH  - Live Birth
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Premature Birth/drug therapy/*epidemiology
MH  - Risk Factors
MH  - Thrombocytopenia/drug therapy/*epidemiology
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - Pregnancy
OT  - Pregnancy complications
OT  - Risk factor
OT  - Therapy modality
EDAT- 2017/08/25 06:00
MHDA- 2018/05/22 06:00
CRDT- 2017/08/25 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/07/06 00:00 [revised]
PHST- 2017/08/02 00:00 [accepted]
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
AID - S0165-0378(17)30093-1 [pii]
AID - 10.1016/j.jri.2017.08.001 [doi]
PST - ppublish
SO  - J Reprod Immunol. 2017 Aug;122:21-27. doi: 10.1016/j.jri.2017.08.001. Epub 2017 
      Aug 4.